Your Cart

Plotkin's Vaccines 7th Edition

Plotkin's Vaccines 7th Edition
-9 %
Plotkin's Vaccines 7th Edition
  • Author: Plotkin
  • ISBN: 9780323357616
  • Publisher: Elsevier
  • Pages: 1504 Pages
  • Dimensions: Hardcover
  • Year Published: 2017
Ex Tax: 273.58€

From the development of each vaccine to its use in reducing disease, Plotkin’s Vaccines, 7th Edition, provides the expert information you need to provide optimal care to your patients. This award-winning text offers a complete understanding of each disease, as well as the latest knowledge of both existing vaccines and those currently in research and development. Described by Bill Gates as "an indispensable guide to the enhancement of the well-being of our world," Plotkin’s Vaccines is a must-have reference for current, authoritative information in this fast-moving field.

New to this edition
  • Covers the new oral cholera and zoster vaccines, as well as newly licensed meningococcal group B vaccines and a newly licensed dengue vaccine.
  • Brings you up to date on successful human trials of Ebola vaccines, an enterovirus 71 vaccine licensed in China, and new recommendations and changes to polio vaccines.
  • Features a new chapter on maternal immunization.
  • Expert Consult™ eBook version included with purchase. This enhanced eBook experience allows you to search all of the text, figures, and references from the book on a variety of devices.
Author Info

By Stanley A. Plotkin, MD, Emeritus Professor of Pediatrics, University of Pennsylvania, Emeritus Professor, Wistar Institute, Former Chief, Division of Infectious Diseases, The Children's Hospital of Philadelphia, Philadelphia, PA; Former Medical and Scientific Director, Pastuer Merieux Connaught (now Sanofi Pasteur), Marnes-la-Coquette, France; Walter Orenstein, MD, DSc (HON), Professor of Medicine and Pediatrics, and Global Health, Emory University; Associate Director, Emory Vaccine Center, Atlanta GA; Bill & Melinda Gates Foundation, Seattle, WA; Former Director, National Immunization Program, Centers for Disease Control and Prevention, Atlanta GA ; Paul A. Offit, MD, Chief, Division of Infectious Diseases, Director, Vaccine Education Center, The Childrne's Hospital of Philadelphia; Professor of Pediatrics, Maurice R. Hilleman Professor of Vaccinology, Perelman School of Medicine, The University of Pennsylvania School of Medicine, Philadelphia, PA. and Kathryn M. Edwards, MD, Sarah H. Sell and Cornelius Vanderbilt Chair in PEdiatrics, Division of Pediatric Infectious Diseases, Vanderbilt University, Nashville TN

Table of Contents:
Section 1: General aspects of vaccination

1. A short history of vaccination

2. Vaccine immunology

3. Correlates of protection

4. The vaccine industry

5. Vaccine manufacturing

6. Evolution of adjuvants across the centuries

7. Vaccine Additives and Manufacturing Residuals in Vaccines Licensed in the United States

8. Passive immunization

9. General immunization practices

Section 2: Licensed Vaccines and Vaccines in Development

10. Adenovirus vaccines

11. Anthrax vaccines

12. Biodefense and special pathogen vaccines

13. Cancer vaccines

14. Cholera vaccines

15. Combination vaccines

16. Cytomegalovirus vaccines

17. Dengue vaccines

18. Diarrhea caused by bacteria

19. Diphtheria toxoid

20. Ebola vaccines

21. Enterovirus 71

22. Epstein-Barr virus vaccines

23. Haemophilus influenzae type b vaccines

24. Hepatitis A vaccines

25. Hepatitis B vaccines

26. Hepatitis C vaccines

27. Hepatitis E vaccines

28. Herpes simplex virus vaccines

29. Human immunodeficiency virus vaccines

30. Human papillomavirus vaccines

31. Inactivated influenza vaccines

32. Influenza vaccine-live

33. Japanese encephalitis vaccines

34. Lyme disease vaccines

35. Malaria vaccines

36. Maternal immunization

37. Measles vaccine

38. Meningococcal Capsular A, C, W, and Y Conjugate Vaccines

39. Mumps vaccines

40. Noninfectious disease vaccines

41. Norovirus

42. Parasitic disease vaccines

43. Pertussis vaccines

44. Plague vaccines

45. Pneumococcal conjugate vaccine and pneumococcal common protein vaccines

46. Pneumococcal polysaccharide vaccines

47. Poliovirus vaccine-inactivated

48. Poliovirus vaccine-live

49. Rabies vaccines

50. Respiratory syncytial virus vaccines

51. Rotavirus vaccines

52. Rubella vaccine

53. Smallpox and vaccinia

54. Staphylococcus aureus vaccines

55. Streptococcus group A vaccines

56. Streptococcus group B vaccines

57. Tetanus toxoid

58. Tick-borne encephalitis virus vaccines

59. Tuberculosis vaccines

60. Typhoid fever vaccines

61. Varicella vaccine

62. Yellow fever vaccine

63. Zoster vaccine

Section 3: New Technologies

64. Technologies for making new vaccines

65. The development of gene-based vectors for immunization

66. Technologies to Improve Immunization

Section 4: Vaccination of special groups

67. Vaccination of immunocompromised hosts

68. Vaccination of human immunodeficiency virus-infected persons

69. Vaccines for international travel

70. Vaccines for health care personnel

Section 5: Public health and regulatory issues

71. Immunization in the United States

72. Immunization in Europe

73. Immunization in the Asia-Pacific region

74. Immunization in developing countries

75. Community Protection

76. Economic analyses of vaccine policies

77. Regulation and testing of vaccines

78. Regulation of vaccines in Europe

79. Regulation of vaccines in low and middle-income countries

80. Vaccine safety

81. Legal issues

82. Ethics


Write a review

Note: HTML is not translated!
Bad Good